ABCG2 is one of the major multidrug resistance (MDR) pumps [36], and targeting ABCG2 may have therapeutic value in overcoming chemoresistance in DLBCL [37–40]. The gene discussed is ABCG2; the disease is diffuse large B-cell lymphoma.